[1] |
SCHMIDT E, KASPERKIEWICZ M, JOLY P. Pemphigus[J]. Lancet, 2019, 394(10201):882-894.
doi: S0140-6736(19)31778-7
pmid: 31498102
|
[2] |
ZHAO L, CHEN Y, WANG M. The global incidence rate of pemphigus vulgaris: a systematic review and meta-analysis[J]. Dermatology, 2023, 239(4):514-522.
doi: 10.1159/000530121
URL
|
[3] |
KRIDIN K. Pemphigus group: overview, epidemiology, mortality, and comorbidities[J]. Immunol Res, 2018, 66(2):255-270.
doi: 10.1007/s12026-018-8986-7
pmid: 29479654
|
[4] |
YUAN H, ZHOU S, LIU Z, et al. Pivotal role of lesional and perilesional T/B lymphocytes in pemphigus pathogenesis[J]. J Invest Dermatol, 2017, 137(11):2362-2370.
doi: S0022-202X(17)31664-0
pmid: 28647348
|
[5] |
ZHOU S, LIU Z, YUAN H, et al. Autoreactive B Cell Differentiation in Diffuse Ectopic Lymphoid-Like Structures of Inflamed Pemphigus Lesions[J]. J Invest Dermatol, 2020, 140(2):309-318,e8.
doi: S0022-202X(19)33203-8
pmid: 31476317
|
[6] |
ZOU Y, YUAN H, ZHOU S, et al. The pathogenic role of cd4+ tissue-resident memory T cells bearing t follicular helper-like phenotype in pemphigus lesions[J]. J Invest Dermatol, 2021, 141(9):2141-2150.
doi: 10.1016/j.jid.2021.01.030
URL
|
[7] |
HOLSTEIN J, SOLIMANI F, BAUM C, et al. Immunophenotyping in pemphigus reveals a TH17/TFH17 cell-dominated immune response promoting desmoglein1/3-specific autoantibody production[J]. J Allergy Clin Immunol, 2021, 147(6):2358-2369.
doi: 10.1016/j.jaci.2020.11.008
URL
|
[8] |
SASCHENBRECKER S, KARL I, KOMOROWSKI L, et al. Serological diagnosis of autoimmune bullous skin di-seases[J]. Front Immunol, 2019, 10:1974.
doi: 10.3389/fimmu.2019.01974
URL
|
[9] |
GOEBELER M, BATA-CSÖRGŐ Z, DE SIMONE C, et al. Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase Ⅱmulticentre, open-label feasibility trial[J]. Br J Dermatol, 2022, 186(3):429-439.
doi: 10.1111/bjd.v186.3
URL
|
[10] |
YAMAGAMI J. B-cell targeted therapy of pemphigus[J]. J Dermatol, 2023, 50(2):124-131.
doi: 10.1111/jde.v50.2
URL
|
[11] |
MURRELL D F, PATSATSI A, STAVROPOULOS P, et al. Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase Ⅱ BELIEVE study[J]. Br J Dermatol, 2021, 185(4):745-755.
doi: 10.1111/bjd.v185.4
URL
|
[12] |
YAMAGAMI J, UJIIE H, AOYAMA Y, et al. A multicenter, open-label, uncontrolled, single-arm phase 2 study of tirabrutinib, an oral Bruton's tyrosine kinase inhibitor, in pemphigus[J]. J Dermatol Sci, 2021, 103(3):135-142.
doi: 10.1016/j.jdermsci.2021.07.002
pmid: 34376340
|
[13] |
ELLEBRECHT C T, BHOJ V G, NACE A, et al. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease[J]. Science, 2016, 353(6295):179-184.
doi: 10.1126/science.aaf6756
pmid: 27365313
|
[14] |
严汝帆, 廖洁月, 郭子瑜, 等. 天疱疮发病机制和靶向治疗的研究进展[J/OL]. 中华皮肤科杂志. 2022[2023-07-10]. http://www.pifukezazhi.com/CN/10.35541/cjd.20210248.
|
|
YAN R F, LIAO J Y, GUO Z Y, et al. Pathogenesis and targeted therapy of pemphigus[J/OL]. Chin J Dermatol, 2022[2023-07-10]. http://www.pifukezazhi.com/CN/10.35541/cjd.20210248.
|
[15] |
中国医疗保健国际交流促进会皮肤科分会. 寻常型天疱疮诊断和治疗专家建议(2020)[J]. 中华皮肤科杂志, 2020, 53(1):1-7.
|
|
Dermatology Branch of China International Exchange and Promotion Association for Medical and Healthcare. Diagnosis and treatment of pemphigus vulgaris: an expert proposal (2020)[J]. Chin J Dermatol, 2020, 53(1):1-7.
|
[16] |
JOLY P, HORVATH B, PATSATSI Α, et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV)[J]. J Eur Acad Dermatol Venereol, 2020, 34(9):1900-1913.
doi: 10.1111/jdv.v34.9
URL
|
[17] |
PORRO A M, HANS FILHO G, SANTI C G. Consensus on the treatment of autoimmune bullous dermatoses: pemphigus vulgaris and pemphigus foliaceus - Brazilian So-ciety of Dermatology[J]. An Bras Dermatol, 2019, 94(2 Suppl 1):20-32.
doi: 10.1590/abd1806-4841.2019940206
URL
|
[18] |
MURRELL D F, PEÑA S, JOLY P, et al. Diagnosis and management of pemphigus: Recommendations of an international panel of experts[J]. J Am Acad Dermatol, 2020, 82(3):575-585.e1.
doi: S0190-9622(18)30207-X
pmid: 29438767
|
[19] |
CHU C Y, LEE C H, LEE H E, et al. Taiwanese dermatological association (TDA) consensus for the management of pemphigus[J]. J Formos Med Assoc, 2023, 122(7):540-548.
doi: 10.1016/j.jfma.2022.12.005
URL
|
[20] |
潘萌, 郑捷. 寻常型天疱疮自身抗体检测及治疗方法的进展[J]. 中华皮肤科杂志, 2018, 51(1):5-9.
|
|
PAN M, ZHENG J. Detection of autoantibodies in and therapeutic methods of pemphigus vulgaris[J]. Chin J Dermatol, 2018, 51(1):5-9.
|
[21] |
BALIGHI K, ASHTAR NAKHAEI N, DANESHPAZHOOH M, et al. Pemphigus patients with initial negative levels of anti-desmoglein: A subtype with different profile?[J]. Dermatol Ther, 2022, 35(4):e15299.
|
[22] |
SHIMIZU T, TAKEBAYASHI T, SATO Y, et al. Grading criteria for disease severity by pemphigus disease area index[J]. J Dermatol, 2014, 41(11):969-973.
doi: 10.1111/jde.2014.41.issue-11
URL
|
[23] |
BOULARD C, DUVERT LEHEMBRE S, PICARD-DAHAN C, et al. Calculation of cut-off values based on the autoimmune bullous skin disorder intensity score (ABSIS) and pemphigus disease area index (PDAI) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus[J]. Br J Dermatol, 2016, 175(1):142-149.
doi: 10.1111/bjd.14405
pmid: 26800395
|
[24] |
陈喜雪, 朱学骏. 天疱疮及大疱性类天疱疮的治疗[J]. 继续医学教育, 2006, 20(23):54-56.
|
|
CHEN X X, ZHU X J. Therapy of pmphigus and bullous pemphigoid[J]. Contin Med Educ, 2006, 20(23):54-56.
|
[25] |
赵珲, 杨宝琦. 药物超敏综合征的遗传易感性研究进展[J]. 中国麻风皮肤病杂志, 2017, 33(10):627-630.
|
|
ZHAO H, YANG B Q. Update of genetic susceptibility of drug-induced hypersensitivity syndrome[J]. Chin J Lepr Skin Dis, 2017, 33(10):627-630.
|
[26] |
CHU C Y, LEE C H, LEE H E, et al. Taiwanese dermatological association (TDA) consensus for the management of pemphigus[J]. J Formos Med Assoc. 2023; 122(7):540-548.
doi: 10.1016/j.jfma.2022.12.005
URL
|
[27] |
WERTH V P, JOLY P, MIMOUNI D, et al. Rituximab versus mycophenolate mofetil in patients with pemphigus vulgaris[J]. N Engl J Med, 2021, 384(24):2295-2305.
doi: 10.1056/NEJMoa2028564
URL
|
[28] |
CHEN D M, ODUEYUNGBO A, CSINADY E, et al. Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect[J]. Br J Dermatol, 2020, 182(5):1111-1119.
doi: 10.1111/bjd.18482
pmid: 31487383
|
[29] |
WANG M, GAO Y, PENG Y, et al. Yearly reduction of glucocorticoid dose by 50% as tapering schedule achieves complete remission for 124 pemphigus vulgaris patients[J]. J Dermatol, 2016, 43(3):325-328.
doi: 10.1111/jde.2016.43.issue-3
URL
|
[30] |
WANG M, LI J, SHANG P, et al. Evaluation of clinical factors and outcome of systemic glucocorticoid therapy discontinuation in patients with pemphigus achieving complete remission[J]. J Dermatol, 2023, 50(10):1347-1352.
doi: 10.1111/jde.v50.10
URL
|
[31] |
ABASQ C, MOUQUET H, GILBERT D, et al. ELISA tes-ting of anti-desmoglein 1 and 3 antibodies in the mana-gement of pemphigus[J]. Arch Dermatol, 2009, 145(5):529-535.
|